Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Psychiatry and Psychology (37)
- Mental and Social Health (6)
- Public Health (5)
- Health Services Research (3)
- Medical Sciences (3)
-
- Psychiatric and Mental Health (3)
- Life Sciences (2)
- Neurosciences (2)
- Pharmacy and Pharmaceutical Sciences (2)
- Alternative and Complementary Medicine (1)
- Analytical, Diagnostic and Therapeutic Techniques and Equipment (1)
- Arts and Humanities (1)
- Behavior and Behavior Mechanisms (1)
- Catholic Studies (1)
- Clinical Epidemiology (1)
- Community Health (1)
- Community Health and Preventive Medicine (1)
- Environmental Public Health (1)
- Epidemiology (1)
- Health Services Administration (1)
- Health and Medical Administration (1)
- History (1)
- International Public Health (1)
- Medical Pharmacology (1)
- Medical Specialties (1)
- Mental Disorders (1)
- Neuroscience and Neurobiology (1)
- Nursing (1)
- Other Psychiatry and Psychology (1)
- Publication
- Publication Type
- File Type
Articles 1 - 30 of 38
Full-Text Articles in Medicine and Health Sciences
Clinical Interview For Psychiatric Assessment, Amresh Srivastava
Clinical Interview For Psychiatric Assessment, Amresh Srivastava
Amresh Srivastava
No abstract provided.
Early Psychosis: A Novel Gateway For Suicide Prevention, Amresh Srivastava
Early Psychosis: A Novel Gateway For Suicide Prevention, Amresh Srivastava
Amresh Srivastava
No abstract provided.
Is The Risk Syndrome For Psychosis Risky Business?, Amresh Shrivastava
Is The Risk Syndrome For Psychosis Risky Business?, Amresh Shrivastava
Amresh Srivastava
No abstract provided.
First Episode Is The Best Episode: Lessons And Limitations In Duration Of Untreated Psychosis (Dup) And Outcome In Schizophrenia, Amresh Srivastava
First Episode Is The Best Episode: Lessons And Limitations In Duration Of Untreated Psychosis (Dup) And Outcome In Schizophrenia, Amresh Srivastava
Amresh Srivastava
First episode is the best episode: Lessons and limitations in duration of untreated psychosis (DUP) and outcom Amresh Shrivastavaa, *, Nilesh Shahb, Meghana Thakarc, Larry Stittd, Gurusamy Chinnasamye
a Executive Director , Mental Health Foundation of India (PRERANA Charitable trust) and Silver Mind Hospital, 209 Shivkripa Complex, Gokhale Road, Thane, Mumbai, Maharashtra, India 400 602, Currently: Assistant Professor of Psychiatry, The University of western Ontario, & associate Scientist, Lawson Health Research Institute, London, Ontario, Canada, E Mail : amresh.edu@gmail.com Professor of Psychiatry LTMG Hospital, University of Mumbai, Sion, Mumbai, Maharashtra, India 400 022 c Clinical psychologist, Silver Mind Hospital, Mumbai, …
Cannabis & Psychosis: The Interface Emerging Frontiers For Research, Amresh Shrivastava
Cannabis & Psychosis: The Interface Emerging Frontiers For Research, Amresh Shrivastava
Amresh Srivastava
INTRODUCTION: CANNABIS CONTINUES TO AFFECT MENTAL HEALTH. ITS ABUSE IS ON RISE GLOBALLY. IN CANADA A RISE BY 30% IN LAST TEN YEARS HAS BEEN OBSERVED IN HIGH SCHOOL STUDENTS. INTERRELATIONSHIP OF CANNABIS WITH PSYCHOSIS AND SCHIZOPHRENIA IS A COMPLEX ONE. CANNABIS IS HIGHLY COMORBID WITH PSYCHOSIS, & RELATED TO FUNCTIONAL DISABILITY AND OUTCOME. IT POSES SEVERAL CHALLENGES IN UNDERSTANDING CAUSAL RELATIONSHIP FOR COMORBIDITY, UNDERLYING NEUROCHEMICAL BASIS AND SPECIFICS OF SERVICE DEVELOPMENT. PREVALENCE OF CANNABIS VARIES FROM 20 TO 50% EARLY PSYCHOSIS. OBJECTIVE OF THIS PAPER IS TO REVIEW AVAILABLE LITERATURE TO IDENTIFY CHALLENGES FOR NEWER TARGETS OF RESEARCH AND …
Response, Remission & Recovery: Need To Review Outcome Measures For Schizophrenia, Amresh Shrivastava, Nilesh Shah
Response, Remission & Recovery: Need To Review Outcome Measures For Schizophrenia, Amresh Shrivastava, Nilesh Shah
Amresh Srivastava
Schizophrenia is a complex neurobehavioral disorder known to be associated with poor outcome. It causes significant disability in patients and burden of care amongst relatives. Outcome in developing countries has been reported to be far better than western world, which has come into scientific scanner recently. Wide gap exists between expectations of outcome amongst patients, relatives, caregivers and professionals, which is possibly because of limitations in measurements tools. Significant number of patients remain marginalized without improvement in social & occupational functioning preventing their integration into mainstream of society despite 'clinically reported good outcome' and significant advancement in treatments. The contemporary …
Should Schizoaffective Disorder Be Dropped From Dsm V, Amresh Srivastava
Should Schizoaffective Disorder Be Dropped From Dsm V, Amresh Srivastava
Amresh Srivastava
No abstract provided.
Should Schizoaffective Disorder Be Dropped From Dsm V, Amresh Srivastava
Should Schizoaffective Disorder Be Dropped From Dsm V, Amresh Srivastava
Amresh Srivastava
No abstract provided.
Treatment Resistant Depression, Amresh Srivastava
Treatment Resistant Depression, Amresh Srivastava
Amresh Srivastava
No abstract provided.
Coping With Clinical Challenges Of Risk-Assessment, Amresh Srivastava
Coping With Clinical Challenges Of Risk-Assessment, Amresh Srivastava
Amresh Srivastava
No abstract provided.
Coping With Clinical Challenges Of Risk Assessment: Towards A New Comprehensive Instrument, Amresh Srivastava, Charles Nelson
Coping With Clinical Challenges Of Risk Assessment: Towards A New Comprehensive Instrument, Amresh Srivastava, Charles Nelson
Amresh Srivastava
No abstract provided.
Catatonia Yesterday, Today, Tomorrow, Amresh Srivastava
Catatonia Yesterday, Today, Tomorrow, Amresh Srivastava
Amresh Srivastava
No abstract provided.
Schizophrenia: General Findings And Current Status, Amresh Srivastava
Schizophrenia: General Findings And Current Status, Amresh Srivastava
Amresh Srivastava
No abstract provided.
Switching And Selecting Atypical Antipsychotic Drugs: Paliperidone, Amresh Srivastava
Switching And Selecting Atypical Antipsychotic Drugs: Paliperidone, Amresh Srivastava
Amresh Srivastava
No abstract provided.
Relapse Prevention In Schizophrenia, Amresh Srivastava
Relapse Prevention In Schizophrenia, Amresh Srivastava
Amresh Srivastava
No abstract provided.
Issues For Dsm-V: The Role Of Culture In Psychiatric Diagnosis, Renato D. Alarcón, Anne E. Becker, Roberto Lewis-Fernández, Robert C. Like, Prakash Desai, Edward Foulks, Junius Gonzales, Helena Hansen, Alex Kopelowicz, Francis G. Lu, María A. Oquendo, Annelle Primm
Issues For Dsm-V: The Role Of Culture In Psychiatric Diagnosis, Renato D. Alarcón, Anne E. Becker, Roberto Lewis-Fernández, Robert C. Like, Prakash Desai, Edward Foulks, Junius Gonzales, Helena Hansen, Alex Kopelowicz, Francis G. Lu, María A. Oquendo, Annelle Primm
Publications from Provost Junius J. Gonzales
No abstract provided.
Social Determinants Of Health And Disease Working Together, Amresh Srivastava
Social Determinants Of Health And Disease Working Together, Amresh Srivastava
Amresh Srivastava
No abstract provided.
Outcome In Schizophrenia: The Long-Term Good Outcome In Schizophrenia Is Not Yet Good Enough, Amresh Srivastava, Meghan Thakar
Outcome In Schizophrenia: The Long-Term Good Outcome In Schizophrenia Is Not Yet Good Enough, Amresh Srivastava, Meghan Thakar
Amresh Srivastava
The illness of schizophrenia has always been a matter of concern for its nature and extent of outcome particularly for its regional and cultural differences. The concept of outcome has been evolving and this study examines the scenario of good outcome in developing countries.
Cognition As An Outcome Measure In Schizophrenia, Amresh Srivastava
Cognition As An Outcome Measure In Schizophrenia, Amresh Srivastava
Amresh Srivastava
No abstract provided.
Mood Symptoms As Comorbidity In Schizophrenia, Amresh Srivastava
Mood Symptoms As Comorbidity In Schizophrenia, Amresh Srivastava
Amresh Srivastava
No abstract provided.
Differential Characteristics Of “Good Outcome Schizophrenia” In A Long-Term Ten Years Study, Mumbai, India, Amresh Srivastava, Meghan Thakar, Nilesh Shah, Larry Stitt
Differential Characteristics Of “Good Outcome Schizophrenia” In A Long-Term Ten Years Study, Mumbai, India, Amresh Srivastava, Meghan Thakar, Nilesh Shah, Larry Stitt
Amresh Srivastava
No abstract provided.
Coping Up Challenges Of Risk Assessment: Towards A New Scale: Sis-Map, Amresh Srivastava, Charles Nelson
Coping Up Challenges Of Risk Assessment: Towards A New Scale: Sis-Map, Amresh Srivastava, Charles Nelson
Amresh Srivastava
No abstract provided.
Outcome In Schizophrenia: How Good Is "Good Outcome" Schizophrenia In Long-Term In Developing Countries, Amresh Srivastava, Meghan Thakar, Nilesh Shah, Larry Stitt
Outcome In Schizophrenia: How Good Is "Good Outcome" Schizophrenia In Long-Term In Developing Countries, Amresh Srivastava, Meghan Thakar, Nilesh Shah, Larry Stitt
Amresh Srivastava
No abstract provided.
Complexity And Limitations Of Stress-Endocrine Research In Mental Health, Amresh Srivastava
Complexity And Limitations Of Stress-Endocrine Research In Mental Health, Amresh Srivastava
Amresh Srivastava
No abstract provided.
Selecting Antidepressant Drugs For Management Of Depression In Primary Care (Part 1), Amresh Srivastava
Selecting Antidepressant Drugs For Management Of Depression In Primary Care (Part 1), Amresh Srivastava
Amresh Srivastava
No abstract provided.
Brain, Mind And Behaviour - Emerging Biological Connections, Amresh Srivastava
Brain, Mind And Behaviour - Emerging Biological Connections, Amresh Srivastava
Amresh Srivastava
No abstract provided.
Baseline Serum Prolactinin Drug Naïve First Episode Schizophrenia Predicts A Positive Clinical And Social Outcome At Five Years, Post Discharge Follow-Up, Amresh Srivastava, Manoj Tamhane, Meghana Thakar, Yves Bureau, Nilesh Shah
Baseline Serum Prolactinin Drug Naïve First Episode Schizophrenia Predicts A Positive Clinical And Social Outcome At Five Years, Post Discharge Follow-Up, Amresh Srivastava, Manoj Tamhane, Meghana Thakar, Yves Bureau, Nilesh Shah
Amresh Srivastava
Serum prolactinis an indicator of tuberoinfundibulardopamine activity. It is reported to increase in wide variety of mental illnesses. It has close relationship with antipsychotic therapy. However, its relationship with psychopathology and outcome is not clear. Serum prolactinlevel was measured in 30 male and 30 female drug naive patients of schizophrenia. Subsequently, these patients were treated with antipsychotics. The severity of psychopathology at the baseline and subsequent improvement at the end of 3 weeks and 6 weeks was assessed on modified brief psychiatric rating scale (mBPRS). Available to follow up at five years 18 males & 22 females patients were reassessed …
Atypical Antipsychotics And Cognitive Enhancement In Schizophrenia: The Current Status, Amresh Srivastava
Atypical Antipsychotics And Cognitive Enhancement In Schizophrenia: The Current Status, Amresh Srivastava
Amresh Srivastava
No abstract provided.
Interface Of Cannabis And Early Psychosis--Priorities In Research And Service Development, Amresh Srivastava
Interface Of Cannabis And Early Psychosis--Priorities In Research And Service Development, Amresh Srivastava
Amresh Srivastava
Introduction: cannabis continues to affect mental health. Its abuse is on rise globally. In Canada a rise by 30% in last ten years has been observed in high school students. Interrelationship of cannabis with psychosis and schizophrenia is a complex one. Cannabis is highly comorbid with psychosis, & related to functional disability and outcome. It poses several challenges in understanding causal relationship for comorbidity, underlying neurochemical basis and specifics of service development. Prevalence of Cannabis varies from 20 to 50% early psychosis. Objective of this paper is to review available literature to identify challenges for newer targets of research and …
Identifying Schizophrenia: Paradigm Shift ‘The Uhr Research’, Amresh Srivastava
Identifying Schizophrenia: Paradigm Shift ‘The Uhr Research’, Amresh Srivastava
Amresh Srivastava
No abstract provided.